Medtech company Edinburgh Biosciences (EBS) is working towards a global solution for the diagnosis and treatment of cataracts. Using a new light-based non-surgical treatment, this cutting-edge treatment has already proved effective in clinical trials.
Ahead of presenting at the 32nd edition of the MedTech investing (MTi) forum on June 6 and 7, Edinburgh Biosciences’ chief executive officer Dr Graham Bell, explains the benefits and potential future applications of the technology.
